Skip to content

Effect of Breathing Maneuvers on Peripheral Glucose Metabolism

Effect of Breathing Maneuvers on Peripheral Glucose Metabolism

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04150627
Acronym
RESPI01
Enrollment
16
Registered
2019-11-05
Start date
2019-11-01
Completion date
2020-04-01
Last updated
2020-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vagus Nerve Stimulation, Insulin Sensitivity, Deep Breathing Maneuver

Brief summary

Two important mechanisms play a major role in the pathogenesis of type 2 diabetes: insulin resistance of the target tissues and the impaired insulin secretion from pancreatic β-cells. Postprandial factors (such as insulin) are perceived by the human brain and induce signals that regulate glucose metabolism via the parasympathetic nervous system. Deep breathing exercise can increase parasympathetic nerve activity. Heart rate variability (HRV) in healthy people can be significantly increased by deep breathing maneuvers, indicating a shift from sympathetic activity to parasympathetic activity. The hypothesis is that this postprandial shift results in a change in peripheral glucose metabolism. In turn, the increased parasympathetic activity could potentially result in a change in postprandial insulin sensitivity or secretion. To test this hypothesis, this study investigates the effect of deep breathing exercise versus normal breathing on insulin sensitivity, on insulin secretion, glucose tolerance, resting energy expenditure, and on parasympathetic tone (analysis of heart rate variability).

Interventions

Deep breathing maneuver to increase parasympathetic nerve activity

Sponsors

University Hospital Tuebingen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* HbA1c \<6.5% * Must be able to understand the explanations of the study and the instructions

Exclusion criteria

* Any relevant (according to investigator's judgment) cardiovascular disease * Neurological and psychiatric disorders * Diabetes mellitus * Asthma

Design outcomes

Primary

MeasureTime frameDescription
Whole body insulin sensitivity0-120 minInsulin sensitivity will be assessed by a 75g OGTT

Secondary

MeasureTime frameDescription
Insulin secretion0-120 minInsulin secretion will be assessed by a 75g OGTT
Glucose tolerance0-120 minGlucose tolerance will be assessed by a 75g OGTT
Resting energy expenditure140-160 min after start of breathing maneuverResting energy expenditure will be assessed by indirect calorimetry
Heart rate variability-35 - 120 minHeart rate variability will be assessed from continuous ecg recordings

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026